Drug firm Ranbaxy Laboratories Limited on Thursday said it has received the pre-qualification from the World Health Organisation (WHO) for its Anti Retroviral Capsule 'Indinavir'.
Pre-qualification are needed to become eligible for exporting drugs to WHO sponsored programmes globally.
"With this new addition, Ranbaxy now has a total of 19 Anti Retrovirals ARVs on the WHO pre-qualification list," Ranbaxy said in a statement.
Anti Retroviral drugs are used in the treatment of person having HIV/AIDS infections.
"Ranbaxy remains committed to provide high quality affordable generic ARV medicines and will continue to dedicate itself in fighting the worldwide struggle against HIV/AIDS,"Ranbaxy Laboratories Ltd CEO and Managing Director Atul Sobti said while commenting on WHO listing.
Ranbaxy's ARVs, including the recently approved WHO pre-qualified products, are manufactured at the Company's state-of-the-art manufacturing facilities, the Gurgaon-based firm said.